Andrew Schiermeier, AvenCell Therapeutics CEO
October 22, 2024 06:00 AM EDTUpdated 06:29 AM
Financing
Cell/Gene Tx

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

Lei Lei Wu

News Reporter

Aven­Cell Ther­a­peu­tics on Tues­day said it col­lect­ed $112 mil­lion to con­tin­ue clin­i­cal stud­ies of two ex­per­i­men­tal acute myeloid leukemia CAR-T cell ther­a­pies.

The Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times